Pd10-09 the Prosper Trial: Chemotherapy-related Endpoints in Patients With Nonmetastatic Castration-resistant Prostate Cancer Treated With Enzalutamide
Year: 2018
Type: article
Abstract: RESULTS: Fifty pts were enrolled and 49 were evaluable for efficacy analysis.At the baseline, the median age was 73 (range 55-86), median PSA level was 28.3ng/mL (2.3-294.3),and Gleason score 8 was present in 45pts (90%).The median duration of initial ADT was 7.5 months(mo, 3.1-19.6)and 48 out of 50 pts experienced PSA progression 1 year while on initial ADT.All cases had treatment history of bicalutamide.Most pts showed high treatment adherence and the median treatment duration was 8.2 mo (0.5-22.9).PSA response rate was 55.1% (n¼27/49; 95%CI 41.3-68.1).The median time to PSA progression (TTPP) was 6.5 mo and the median radiographic progressionfree survival (rPFS) was 11.0 mo.The median Overall Survival was not reached.The treatment was well tolerated with 30% of grade 3 events.CONCLUSIONS: This is the first study to investigate the efficacy of AA+P in ADT poor responders.Our study demonstrated a consistent result on PSA response rate with previous studies, this might suggest that AA+P should be considered as an option for initial ADT poor responders.TTPP and rPFS were shorter than the results of previous studies.This trend was also reported in chemotherapy setting (Angelergues 2014 and Aljundi 2016); accordingly, shorter duration of effectiveness might still remain as a considerable point of treatment for this population.
Source: The Journal of Urology
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2795429270